MAY 11, 2017 12:00 PM PDT

Impact of Next-Generation Sequencing on Precision Medicine

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Vice President and Distinguished Scientist Illumina
      Dr. Schroth is currently a Vice President and Distinguished Scientist at Illumina where he directs the Core Applications Group based in San Diego.

      He obtained his Ph.D. in biochemistry from the University of California at Davis and has been working in the field of next-generation sequencing (NGS) for more than a decade as part of Illumina (and Solexa).

      In his research Dr. Schroth uses NGS to study genomics, gene structure, expression and regulation and applies this to genomic projects in the fields of cancer, microbiology and infectious disease.

      Over the course of his career Dr. Schroth has published over 90 peer reviewed research papers and holds 17 U.S. patents.


    It was 10 years ago that Illumina first launched the Genome Analyzer II, the world’s first high-throughput sequencing platform.  That system could produce one billion bps of sequence information of data per run, which helped ignite a new revolution in genomics.   The past decade has seen further advances in data throughput, cost reductions, improved data quality and, most importantly, applications of next-generation sequencing.  In this talk we will discuss how NGS has specifically enabled entire new areas of research and testing in the field of precision medicine, including human genome and exome sequencing, human microbiome analysis, and elucidation of the molecular details of human cancer.  This talk will highlight the latest improvements in NGS and the interrelationships between science and technology in the field of personalized medicine.

    Show Resources
    Loading Comments...